Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
letter
. 2026 Jun 18;41(10):2787–2788. doi: 10.1002/mds.70414

Alkaline Phosphatases: A Potential Cause of Variability in Therapeutic Response to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion?

Manon Auffret 1,2,✉, Marc Vérin 3,4
PMCID: PMC13686124  PMID: 42315479

Foslevodopa/foscarbidopa (fLD/fCD) is a highly soluble levodopa/carbidopa monophosphate prodrug formulation administered via continuous subcutaneous infusion for the management of motor complications in Parkinson's disease (PD). 1 While fLD/fCD sustains stable levodopa/carbidopa exposure, 2 , 3 underpinning both its motor and non‐motor efficacy, 1 , 4 therapeutic failure has been documented in a subset of PD patients who had previously responded satisfactorily to other levodopa‐based therapies, including oral treatment and/or levodopa/carbidopa intestinal gel (LCIG). 1 , 5 Moreover, compared to oral and enteral administration of levodopa, a delayed detection of plasma levodopa levels is observed following fLD/fCD administration. 2 , 3 Upon subcutaneous delivery, fLD/fCD undergoes enzymatic conversion to its pharmacologically active form (levodopa/carbidopa) via alkaline phosphatases (ALPs). 2 ALPs are isoenzymes that are distributed throughout the body (tissue‐specific and tissue‐nonspecific isoforms) and anchored to the outer surface of the cell membrane, where they mediate the hydrolytic cleavage of organic phosphate esters within the extracellular space. 6 , 7 ALPs levels and/or activity are influenced by genetics (mutations in the ALPL gene, encoding tissue‐nonspecific ALPs), age, gender, physiological states (pregnancy, menopause), anthropometric factors (ie, body mass index, bone density), activators/inhibitors (including medications), and various clinical conditions (mainly liver diseases, bone disorders, and cancers). 6 , 7 Nutritional deficiencies, particularly those involving magnesium and zinc (both essential enzyme cofactors), also reduce ALPs activity. 7 If ALPs were to represent a rate‐limiting step in prodrug conversion—a hypothesis that remains to be empirically tested—any inter‐ and/or intra‐individual variability in ALPs levels and/or activity could theoretically translate into variability in levodopa plasma levels and clinical outcomes following fLD/fCD administration in PD patients. Reduced ALP activity may result in insufficient prodrug conversion, leading to underdosing, persistent “off” periods, or treatment failure, whereas elevated ALP activity could produce faster or more erratic conversion, potentially triggering dyskinesia. Beyond previously discussed causes of non‐response either related to incorrect diagnosis, fLD/fCD (symptoms unresponsive to dopaminergic stimulation, persistence of fluctuations, or reduction of dopaminergic medications potentially leading to dopamine agonist withdrawal syndrome), or the subcutaneous route, 4 , 5 we propose that ALPs represent a currently underexplored yet clinically significant source of pharmacokinetic variability in fLD/fCD therapy. To evaluate this hypothesis, empirical studies are first needed to establish whether ALPs variation correlates with clinically meaningful differences in levodopa exposure and outcomes. Such findings would then warrant systematic investigation to optimize PD patient outcomes and ensure treatment safety.

Author Roles

(1) Research Project: A. Conception, B. Design, C. Acquisition, D. Analysis, E. Data Interpretation; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript Preparation: A. Writing of the First Draft, B. Review and Critique, C. Final Approval.

M.A.: 1A, 1B, 1C, 1D, 1E, 3A.

M.V.: 3B, 3C.

Acknowledgment

Open access publication funding provided by COUPERIN CY26.

Funding agency: None.

Relevant conflicts of interest/financial disclosures: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this letter.

Data Availability Statement

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

References

  • 1. Aldred J, Freire‐Alvarez E, Amelin AV, et al. Continuous subcutaneous foslevodopa/foscarbidopa in Parkinson's disease: safety and efficacy results from a 12‐month, single‐arm, open‐label, phase 3 study. Neurol Ther 2023;12(6):1937–1958. 10.1007/s40120-023-00533-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Rosebraugh M, Liu W, Neenan M, Facheris MF. Foslevodopa/foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion. J Parkinsons Dis 2021;11(4):1695–1702. 10.3233/JPD-212813 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Rosebraugh M, Stodtmann S, Liu W, Facheris MF. Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa‐carbidopa intestinal gel delivered to the jejunum. Parkinsonism Relat Disord 2022;97:68–72. 10.1016/j.parkreldis.2022.03.012 [DOI] [PubMed] [Google Scholar]
  • 4. Koeglsperger T, Berberovic E, Dresel C, et al. Real‐world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations. J Neural Transm 2026;133(2):347–359. 10.1007/s00702-025-02911-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Roszmann A, Piekarski R, Mongird‐Niklewski P, Sławek J. Loss of therapeutic efficacy following the switch from levodopa/carbidopa intestinal gel therapy to subcutaneous foslevodopa/foscarbidopa infusion in a patient with advanced Parkinson's disease. Neurol Neurochir Pol 2026;60(1):111–113. 10.5603/pjnns.108714 [DOI] [PubMed] [Google Scholar]
  • 6. Le‐Vinh B, Akkuş‐Dağdeviren ZB, Le NM N I, Bernkop‐Schnürch A. Alkaline phosphatase: a reliable endogenous partner for drug delivery and diagnostics. Adv Ther 2022;5(2):2100219. 10.1002/adtp.202100219 [DOI] [Google Scholar]
  • 7. Sikaris KA, Rankin K. Interpreting alkaline phosphatase in clinical practice: integrating analytical advances and physiological context. Pathology 2026;58(2):172–180. 10.1016/j.pathol.2025.11.005 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.


Articles from Movement Disorders are provided here courtesy of Wiley

RESOURCES